Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
State Policy
Are Prescription Price Controls in New Jersey’s Future?
Earlier this year in the state of New Jersey, a state senator introduced Senate Bill 977, “Prohibits excessive charges for drugs…
Pfizer Settles with New York Over Deceptive Advertising
On October 11, 2018, New York Attorney General Barbara D. Underwood announced a settlement with Pfizer, Inc. for deceptive…
AbbVie Sued by California Insurance Commissioner for Humira Kickback Scheme
On Tuesday, September 18, 2018, California’s insurance commissioner filed a complaint against AbbVie, Inc., alleging a kickback…
California Governor Signs SB 212 Into Law
We previously wrote about the California legislation that established a statewide take-back system for sharps and medications. On…
California Senate Passes Drug and Needle Take-Back Program
Earlier this month, the California State Senate passed SB 212, via unanimous vote. The bill aims to establish a statewide…
California Court Dismisses PhRMA Transparency Lawsuit
On August 30, 2018, the United States District Court for the Eastern District of California dismissed a lawsuit brought by the…
AstraZeneca Agrees to Settle Off-Label Marketing Suits
Recently, AstraZeneca Plc agreed to pay $110 million to settle two Texas claims that alleged the company cheated Texas’ Medicaid…
California May Pass Legislation to Regulate PBMs
We have previously written about pharmacy benefit managers (PBMs) and the way states are trying to regulate them through…
The Year of the State
Following on the heels of more than 40 state legislatures, the U.S. Congress passed a federal right-to-try law giving patients…
Price Transparency: It’s Not Just Pharma…
Price transparency has been a “buzz phrase” for the pharmaceutical industry for the last several years. However, the state of New…